AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
SG&A Expenses Over TimeStrong
Percentile Rank67
3Y CAGR+1.5%
5Y CAGR+60.2%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+1.5%/yr
Annual compound
5Y CAGR
+60.2%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
10.5x
Strong expansion
Streak
2 yr
Consecutive declineStrong
PeriodValueYoY Change
TTM$13.34M-5.2%
2024$14.07M-4.7%
2023$14.76M+15.8%
2022$12.75M+173.2%
2021$4.67M+269.0%
2020$1.26M-27.0%
2019$1.73M-